Full Press Release Details
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
LOS ANGELES, October 16, 2025: Lunai Bioworks, Inc. (Nasdaq:
LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.
On April 14, 2025, Nasdaq Staff notified the Company that its common stock
had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2).
However, Staff has since determined that for the 11 consecutive business days from September 30, 2025 through October 14, 2025, the closing
bid price of Lunai Bioworks' common stock was at or above $1.00 per share. As a result, the Company has now regained compliance
with the rule and remains eligible for continued listing on The Nasdaq Capital Market.
"This compliance milestone reflects our commitment to strategic execution
and shareholder value during a transformative period for Lunai Bioworks," said David Weinstein, Chief Executive Officer. "We
remain focused on advancing our AI-powered platform and delivering long-term impact across drug discovery and biodefense."
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company
pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on
dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society
from emerging threats.
Chief Executive Officer